Cargando...
Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations
Gastric and esophageal cancers represent a major global cancer burden and novel approaches are needed. Despite recent improvements in outcomes with trastuzumab and ramucirumab the prognosis for advanced disease remains poor, with a median overall survival of 1 year. Comprehensive genomic characteriz...
Guardado en:
| Publicado en: | J Gastrointest Oncol |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
AME Publishing Company
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4570917/ https://ncbi.nlm.nih.gov/pubmed/26487950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2015.037 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|